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INTRODUCTION
Cyclophosphamide is an alkylating agent commonly used in 
antineoplastic and immunosuppressive therapies. Its side effects 
when used in high doses include bone marrow depression, al-
opecia, mucositis, sterility, hemorrhagic cystitis, and symptom-
atic hyponatremia due to severe water intoxication [1,2]. 
Severe hyponatremia (serum sodium<120 mmol/L) is a 
serious electrolyte disorder with life-threatening neurological 
complications and is rarely induced by low dose cyclophos-
phamide (<20 mg/kg). Until now, there has been only one re-
ported case of severe hyponatremia with generalized seizure 
from low-dose intravenous cyclophosphamide based chemo-
therapy in a breast cancer patient [3]. We report a case of se-
vere, symptomatic hyponatremia that developed in a female 
breast cancer patient following the first cycle of chemotherapy 
containing low-dose cyclophosphamide.
‘
CASE REPORT
A 56-year-old woman was scheduled to receive four cycles 
of adjuvant chemotherapy containing doxorubicin 60 mg/m
2 
and, cyclophosphamide 600 mg/m
2 (AC) and thereafter four 
cycles of adjuvant chemotherapy containing paclitaxel 175 mg/ 
m
2 (T) with a three-week time interval for stage IIB (pT2N1M0) 
invasive ductal carcinoma of the right breast. Her past medi-
cal history included hypertension and cerebral hemorrhage in 
the left temporal lobe that developed 15 years prior, for which 
she was treated properly with propranolol 40 mg, nifedipine 
30 mg, enalapril maleate 10 mg, and acetyl salicylic acid 100 
mg once daily without experiencing any side effects. Her labo-
ratory tests and 2-D echocardiogram were normal before the 
first cycle of adjuvant chemotherapy. During the first cycle of 
adjuvant chemotherapy containing doxorubicin 90 mg and 
cyclophosphamide 900 mg, she was hydrated with 1.0 L of iso-
tonic saline and received antiemetic therapy consisting of dexa-
methasone and palonosetron. She was discharged the follow-
ing day without any immediate side effects of the chemother-
apy. Her serum electrolyte level was not routinely checked prior 
to discharge. She went to the emergency department the fol-
lowing day (50 hours after adjuvant chemotherapy) due to gen-
eral weakness, nausea, vomiting, and edema. Just after arriving 
at the hospital, she developed a generalized seizure with con-
vulsions, following a period of impaired consciousness and 
incoherent speech. A Glasgow Coma Score of 3 was noted. 
Her vital signs were blood pressure 140/80 mmHg, pulse rate 
78 beats/min, and body temperature 37.1°C. Laboratory tests 
showed the followings: hemoglobin 14.2 g/dL, platelets 201,000/ 
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Cyclophosphamide is commonly used in the treatment of malig-
nant diseases. Symptomatic severe hyponatremia induced by 
low-dose cyclophosphamide is very uncommon worldwide. Re-
cently we experienced a case of a 56-year-old woman with 
breast cancer who developed severe hyponatremia with gener-
alized seizure after the first cycle of adjuvant chemotherapy with 
doxorubicin and cyclophosphamide. Her laboratory test showed 
a serum sodium of 116 mmol/L. Her hyponatremia was initially 
treated with hypertonic saline solution and furosemide. She 
completely recovered without neurological deficits after slow 
correction of the serum sodium concentration over two days. 
Clinicians must always keep in mind that life-threatening acute 
hyponatremia can be induced by intravenous cyclophospha-
mide during chemotherapy, even if the dosage is low.
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mm
3, white blood cell count 7,800/mm
3, blood urea nitrogen 
8.2 mg/dL, serum creatinine 0.65 mg/dL, serum sodium con-
centration 116 mmol/L, serum potassium 3.6 mmol/L, serum 
chloride 87 mmol/L, serum albumin 4.3 g/dL, serum osmolal-
ity 254 mOsmol/kg, and urine sodium concentration 34 mmol/
L. Urine analysis showed specific gravity 1.039, pH 6.5, protein -, 
blood -, WBC/high powered field (HPF) 0-1, red blood cells/ 
HPF 0-1. The brain computed tomography (CT) revealed no 
interval change as compared to the previous brain CT. To cor-
rect her severe symptomatic hyponatremia, urgent medical 
treatment with hypertonic saline solution and furosemide was 
initiated carefully. Within 12 hours, her serum sodium concen-
tration rose gradually from 116 to 126 mmol/L and the patient 
slowly recovered from her neurological symptoms. The serum 
sodium concentration was gradually corrected to 136 mmol/L 
by infusion of isotonic saline for the next two days (Table 1). 
She was discharged asymptomatically after 10 days and was 
admitted to the hospital for the second adjuvant chemothera-
py. She was treated with 20% dose reduction of chemotherapy 
and we checked her body weight, electrolytes, and input/out-
put daily to prevent severe hyponatremia induced by low dose 
cyclophosphamide. Although she had water retention with a 
2 kg-weight gain during the chemotherapy, she was success-
fully treated with hypertonic saline solution and furosemide 
without any neurologic symptoms. We will treat her with adju-
vant AC (doxorubicin + cyclophosphamide) chemotherapy as 
initially scheduled.
DISCUSSION
Symptomatic hyponatremia with a generalized seizure was 
observed in our patient 48 hours after treatment of the first 
cycle of AC chemotherapy. Hyponatremia usually occurs 4-12 
hours after the administration of cyclophosphamide, although 
sometimes not until 48 hours afterwards, as in our case, and 
returns to normal in around 24 hours. The antidiuretic effect 
seems to be related to the appearance of active alkylating me-
tabolites of cyclophosphamide [4].
We suspected intravenous low-dose cyclophosphamide-
based chemotherapy as the cause of severe hyponatremia since 
other causes were ruled out. She had been diagnosed with cere-
bral hemorrhage with hypertension in 1996. A cerebral hem-
orrhage lesion in her past medical history could have caused   
a generalized seizure with convulsions, but her brain CT and 
magnetic resonance imaging scan showed no interval changes 
before and after the seizure attack, and she recovered from her 
neurologic symptoms after the correction of her hyponatremia. 
The enalapril maleate that she took as an antihypertensive drug 
could also have caused hyponatremia. However, she had been 
well, without any symptoms related to hyponatremia during 
the treatment of hypertension with enalapril maleate. However, 
it is necessary to keep in mind the possibility that her past med-
ical history, including the cerebral hemorrhage and enalapril 
maleate medication, may have been predisposing factors that 
deteriorated her severe hyponatremic symptoms. 
In this case, she had a 3.5 kg-weight gain after chemothera-
py. Although we performed overhydration on her to prevent 
hemorrhagic cystitis, this was not enough to explain her weight 
gain and severe hyponatremia. After her discharge from the 
hospital, she insisted on a low salt diet due to her concern about 
hypertension. Water intoxication induced by low-dose cyclo-
phosphamide might have been accelerated due to overhydra-
Table 1. Serum electrolytes, urine electrolytes, other laboratory findings, body weight, and neurological status according to time intervals
Normal range
Before  
chemotherapy
24 hr after  
chemotherapy 
50 hr after  
chemotherapy  
(at Emergency  
Department)
62 hr after  
chemotherapy
 4 days after  
chemotherapy
Hemoglobin (g/dL) 11.7-16  12.7 NC 14.2 NC 10.9
Hematocrit (%)    35-47 36.6 NC 40.9 NC 31.3
Serum sodium (mmol/L)    136-145  141 NC 116 126 136
Serum potassium (mmol/L)    3.5-5.3  4.5 NC 3.6 4.9 3.3
Serum osmolarity (mOsmol/kg)    275-295 NC NC 254 NC NC
Albumin (g/dL)    3.5-5.2 4.5 NC 4.3 NC NC
BUN (mg/dL)      7-20 17.2 NC 8.2 9.7 8.1
Creatinine (mg/dL)    0.6-1.1 0.75 NC 0.65 0.65 0.55
Urine sodium (mmol/L) NC NC 34 NC 141
Urine osmolarity (mOsmol/kg)    300-900  NC NC 189 NC 647
Body weight (kg) 52.95 56.65 NC NC 53.24
Neurological status Clear Clear Semicomatous
mentality, seizure
Lethargic mentality No neurological  
deficits
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tion and her low salt diet.
Severe hyponatremia has been previously reported in pa-
tients treated with high-dose cyclophosphamide (30-40 mg/
kg) and moderate-dose (20-30 mg/kg) intravenous cyclophos-
phamide [5-9]. There have been four malignant disease cases 
in which severe symptomatic hyponatremia was reported from 
low-dose intravenous cyclophosphamide therapy including, 
our case and other malignant disease cases [3,10]. Two cases, 
including our case, were women with breast cancer suffering 
from severe hyponatremia after adjuvant chemotherapy, and 
another was a man with multiple myeloma suffering from severe 
hyponatremia after a single dose of low-dose cyclophospha-
mide. The last one was a woman with metastatic adenocarci-
noma of small salivary glands who received a cycle of AC che-
motherapy and concomitant use of cisplatin [11]. Those data 
are summarized in Table 2.
The mechanisms of hyponatremia induced by cyclophos-
phamide have not been clearly understood, but there are some 
possible mechanisms of cyclophosphamide induced hypona-
tremia. Harlow et al. [6] suggested a syndrome of inappropri-
ate antidiuretic hormone secretion. That hypothesis is corrob-
orated by the postmortem examination that was performed 
on one patient who received high-dose cyclophosphamide, 
and demonstrated loss of Herring’s bodies and degranulation 
of various hypothalamic neurosecretory organelles. The cyclo-
phosphamide metabolite could act indirectly by causing ADH 
release; this has been demonstrated with ifosfamide, a close 
structural analogue to cyclophosphamide. Lee et al. [12] spec-
ulated that the antidiuretic effect of cyclophosphamide might 
be related to increased renal action of vasopressin by alkylating 
metabolites, and water retention might involve a direct tubular 
effect of cyclophosphamide metabolite on the collecting duct 
epithelium, because it was demonstrated in a case with estab-
lished diabetes insipidus that developed cyclophosphamide 
associated antidiuresis without vasopressin secretion [13]. There-
fore, further studies will be necessary to evaluate the molecular 
mechanisms of hyponatremia induced by cyclophosphamide 
and establish dose dependant relationships of cyclophospha-
mide with the severity of hyponatremia.
We have learned many lessons from this case. First, overhy-
dration and hypotonic saline solution use should be avoided 
in prechemotherapy hydration. Second, common symptoms 
like nausea, vomiting, and general weakness due to chemo-
therapy might be a sign of severe hyponatremia. Third, clini-
cians must pay more attention to a patient with comorbidities 
such as nephritic syndrome or concurrent medications that 
can be associated with hyponatremia. 
In conclusion, clinicians must always keep in mind that life-
threatening acute hyponatremia can be induced by intravenous 
cyclophosphamide during chemotherapy, even if the dosage is 
low.
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